Background: Currently, over 20 genes have been defined that can confer susceptibility for high-risk breast cancer. Although research has proved the utility of multiple-gene sequencing in the assessment of breast cancer risk, there is little data from China patients. Here, we use a multiple-gene sequencing panel to identify the variant spectrum in Chinese high-risk breast cancer subjects.
Introduction
Breast cancer is the most common cancer in women worldwide with over 1.6 million new cases diagnosed and over 520,000 deaths annually (Globocan 2012, http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx). Improved treatment has contributed to steady declines in breast cancer mortality in developed countries (1) . However, breast cancer incidence is continuously rising in nearly all countries and mortality rate stays high in most Asian countries (Globocan 2012). In China, there is an estimated 272,000 total cases annually (269,000 in women) and 70,000 total deaths (69,000 in women) (2) .
Up to 10% of breast cancer is caused by the inheritance of germline mutations in susceptibility genes (3) . BRCA1 and BRCA2 are the predominate genes, while other genes such as PALB2, TP53, PTEN may also contribute to genetic risk and screening susceptible population for such mutations can lead to reduced mortality from breast and ovarian cancer (4) (5) (6) (7) . There is a considerable diversity in mutations in BRCA1, BRCA2 and other genes in different populations, requiring studies worldwide (3, (8) (9) (10) (11) . Studies of germline mutation spectrum have been carried out in Asian populations, but comparatively few in Chinese populations (12) (13) (14) (15) (16) (17) (18) . This study aims to identify the spectrum of germline variants in a large panel of cancer genes in selected Chinese breast cancer families.
Method Participants and Selection Criteria
A total of 829 breast cancer patients who met genetic risk evaluation criteria according to National Comprehensive Cancer Network (NCCN) guidelines for breast and/or ovarian cancer genetic assessment (version1.2014) were recruited from 2010 to 2016. All patients met the high risk criteria: 1.early age-ofonset, people suffer breast cancer under age 45; 2.patients who have at least two primary breast cancer;
3.with a family history: whose first degree relatives have breast cancer or ovarian cancer. Of the 829 breast cancer patients, 593 came from Harbin Medical University Cancer Hospital, and 236 came from Shenzhen Second People's Hospital of China. All of them did not have previous breast cancer susceptibility gene testing.
Ethics, consent and permissions
Every participant signed an institutional review board-approved informed consent document offered by Harbin Medical University Cancer Hospital, Shenzhen Second People's Hospital or BGI Shenzhen. The consent informed the participants that their test data would be used for research. Clinical data and family disease history information were including patient gender, age at diagnosis of breast cancer, breast cancer molecular subtype, site, personal history of other cancers, and family history of cancer in close blood relatives: diagnosis age, tumor type, and health status. The clinical information is shown in Supplementary   Table S1 .
Gene Panel
All breast cancer samples were subjected to the target sequencing using a multiple-gene panel and subsequent variant analysis. A total of 115 target genes were selected through a review of databases 
Variant Classification
Variants were annotated by ANNOVAR and then classified as pathogenic, variants of uncertain significance (VUS) and benign according to American College of Medical Genetics (ACMG) recommendations(40, 41) by a semi-automatic pipeline called VCE for interpretation of sequence variants.
The detailed evidence can be found in Supplementary Table S4 . Most pathogenic variants detected by next-generation sequencing were confirmed by conventional PCR-Sanger sequencing, except variants located in repeat regions.
Gastroscopy of mutation carrier
Mutation carrier families accepted the clinical screening such as gastroscopy, fibercolonoscopy, breast ultrasound and serum tumor marker detection (CEA, CA199, CA742) based on the hereditary cancer susceptibility gene research progress. Up to now, gastroenteric precancerous lesions have been observed in 3 families with ATM, PMS2, and PALB2 pathogenic variants respectively.
Functional analysis of Variant of uncertain significance
Functional analysis of variants from BRCA genes was conducted by Ranomics Inc. To validate variants occurred in RING domain, they measured if mutated BRCA1 showed decreased ligase activity and weaker protein-protein interactions in its heterodimer with the BARD1 protein(42) They also validated variants in BRCT domain by comparing growth speed between dysfunctional variants and normally functioning variants in the BRCA1 BRCT domain (43) .
Statistical analysis
The statistics in this research is performed by R 3.5.1. The significance between mutation prevalence and characteristics is compared by Chi square test or Fisher exact test depending on case number.
Results
Variants classification pipeline. Non-carrier and non carrier. There a also a small proportion of people carried more than one variants that belongs to different groups.
BRCA1 and BRCA2 Pathogenic Variants and Clinical characteristic
The prevalence of BRCA1 and BRCA2 pathogenic variant in 829 breast cancer patients is 5.0% and 6.5% respectively. The BRCA1/2 mutation frequency found in our research is similar with the results from other studies with Chinese population but distinct from reports based on other populations (Table1). (77) * Means genetic defects in this gene will result in autosomal recessive disorder.
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome

Clinical screening of mutation carrier
Some mutation carrier families (other genes pathogenic mutation carriers, excluding BRCA1, BRCA2 or PALB2) received further clinical screening as described in method section. Pre-cancer lesions were found in three families. In the first family, one PMS2 pathogenic variant carrier (proband, study ID: 30033, diagnosed with breast cancer at 55 years old) was found to have colon polyp (diagnosed at 58 years old).
Her sister (study ID: 30033FM1), who is also a breast cancer patient (diagnosed at 44 years old), was found to have colon villioustublar adenoma with low-grad intraepithelial neoplasia (diagnosed at 52 years old) and the lesion was removed by endoscopic resection [ Figure 3A ]. They were also both found to have stomach fundus polyp and gastritis. Their father and father's sister already died because of stomach cancer. They were recommended to do examination again one year later. In the second family, one ATM gene mutation carrier who was diagnosed with breast cancer at age 81, (proband study ID30491) refused the clinical screening because of advanced age. But he has two daughters with ATM gene mutation. One of them (study ID: 30491FM2) had been diagnosed with breast cancer (diagnosed at 39 years old). The other one (study ID: 30491FM3) was found to have colon tubular adenoma, atrophic gastritis and stomach fundus erosion in this screening (at 58 years old) [ Figure 3B ]. In the third family, the proband (study ID: 30306) is both ATM and PALB2 mutation carrier (diagnosed with breast cancer at 47 years old). She was found to have colon villioustublar adenoma and superficial gastritis with erosion (diagnosed at 48 years old) [ Figure 3C ]. Her niece (study ID: 30306FM2) was found to have rectal tubular adenoma (diagnosed at 39 years old), however, she is not a mutation carrier. All adenoma were removed during colonoscopy. 
Discussion
The major hurdle in utilizing NGS data lies in how to interpret the genotype-phenotype relationships, especially in clinical settings. First key element is automatic: A larger number of germline variants are called after WES/WGS sequencing, it will be time-consuming if we completely depend on manual judgement. Secondly, the standardization: A high proportion of variant classifications are discrepant between intra-and inter-laboratory settings resulting from different understanding on ACMG guideline and a lack of unified standard (78) . So the experts review based on comprehensive evidence is also necessary.
And the classification evidence should be easily exhibited for peer review. Taken above concerns into consideration, we developed VCE to classify variants identified in our study. It could do the classification automatic based on objective evidence and marked variants that need manual check.
It is also open to the further extend of literature database, it will become more applicable and less manual intervention will be needed.
There is a breast cancer cumulative risk of people carrying a BRCA1, BRCA2 or PALB2 pathogenic variation (79, 80) . which demonstrated that the carriers of mutations in these susceptibility genes have a significantly higher risk of breast cancer. Additional hereditary breast cancer-related susceptibility genes have also been studied by multiple gene panel sequencing previously (56) . However, only a limited number of such studies have been conducted in China, due to the high cost of massive sequencing. Our data demonstrates a pathogenic mutation frequency in BRCA1 and BRCA2 of 11%, similar to other studies.
Another large Chinese study was published from Shanghai, reporting a 9.1% frequency in women with at least one breast cancer risk factor (14) . They identified the BRCA1 c.5470_5477del mutation as common in their population, a mutation we also report as a recurrent mutation. Besides BRCA1 and BRCA2, PALB2
and ATM also showed high prevalence as Xie et al 's research(11) based on unselected breast cancer patient. But HMMR and BRAD1 shows higher positive rate which remind those 2 genes may be important for high risk patients. The total positive rate of breast cancer related genes is 15.4% in our cohort, a median rate between familial breast cancer and early onset breast cancer. In our cohort, patients with age less than 40 is not associate with BRCA1/2 mutation carrier.
Shao et al 's research (14) indicates the cut off value may be set to 45. Our results confirm that conclusion.
The susceptibility genes of other cancer are mainly about gastric cancer and AML. Those patients are enrolled in our research mainly by their family history. Our clinical follow up also confirm that. So, a comprehensive clinical genetic consulting including multiple department is needed. Otherwise the patient's susceptibility genes of other cancer may be not well-treated.
Another problem in variants interpretation is VUS. In our cohort, a total of 2632 VUS spots on 115 genes were identified in 787 out of 829 subjects, among which 684(82.5%) patients carried more than one VUS.
According to other data from 1112 Shenzhen HBC high risk people, VUS rate of 21 breast cancer related gene is 55.04%. BRCA1 and BRCA2 in our data had (5.1%) and (12.1%) VUS rate respectively. Therefore, Chinese cohorts generally present a higher VUS rate than data from Myraid (81) . It would be important to lower the frequencies of VUSs in Chinese cohorts. Recently, the large scale of variants validation on BRCA1 is conducted (82) . This research provided new evidence for RING and BRCT domain in BRCA1.
But there are still some short comes when applying in clinical. For instance, all the editing was conducted in same cell line. However, the real patient will have a more complicate genetic background. It's critical to confirm if those validation is consistent with clinical observation.
Our research is a multiple-gene test based hereditary breast cancer research with a big data set in China, which provides a comprehensive perspective of the breast cancer pathogenic variation in susceptibility gene as well as VUS spectrum in Chinese. With our data, we present the variant spectrum of 115 hereditary cancer-related susceptibility genes in 829 high-risk breast cancer patients.
In this research, we develop a semi-automatic variation classification tools and identified the function of five BRCA1 VUS in Chinese cohort. By analyzing our data, we provide a comprehensive overview of the pathogenic variant detection rate and the difference between Chinese and other populations. We have established screening pipeline and explorer the usage of multiple-gene hereditary cancer test in clinical practice of China. This work will aid the prevention and treatment of breast cancer in the Chinese people. 
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